The European Medicines Agency (EMA) has today issued a landmark draft guidance entitled “Guideline on quality aspects of phage therapy medicinal products,” marking a significant regulatory advance for bacteriophage-based pharmaceuticals in Europe. This guidance specifically targets the growing interest in phage therapies as antimicrobial drugs, spurred by challenges such as rising antimicrobial resistance and the need for sophisticated alternatives to traditional antibiotics.

Bacteriophages—viruses that infect and destroy bacteria—are being actively explored as next-generation therapeutics to address pathogenic bacteria and difficult-to-treat infections. The newly published document establishes comprehensive regulatory expectations for applicants seeking marketing authorization for phage therapy medicinal products (PTMPs). It outlines the required documentation and practices for the manufacturing, characterization, analytical control, reference standards, and long-term stability of bacteriophage active substances and finished products destined for human use.

Notably, phage therapies differ in several biological respects from existing biologics and gene therapies. The guidance therefore addresses unique phage characteristics such as host specificity, rapid self-propagation, evolutionary potential, and risks related to horizontal gene transfer. These factors could impact manufacturing consistency, product safety, and quality controls, necessitating a separate regulatory approach from conventional biologics.

Key requirements set forth for applicants include formal phage characterization, covering taxonomic classification, target pathogen identification, intended potency, genome type and size, and detailed disclosure of any genetic or chemical modifications. Manufacturers must provide extensive data around the origin and preparation of both bacterial cell banks and phage seed lots, utilizing master and working seed lot systems. The guidance also introduces a mandate for full bacterial genome sequencing and bioinformatic analysis, supporting identity, purity, cell viability, phage sensitivity, and antibiotic susceptibility checks.

All phages used in seed lots must be lytic, with manufacturers required to detail the origin and history of these seed lots. Analytical profiling—using electron microscopy, image analysis, nucleic acid sequencing, and infectious titer plaque assays—will be required to confirm phage structure, genotype, phenotype, and potency. Standards referenced include EU pharmacopoeial chapters and international guidelines on biotechnological production of biologicals.

Additional requirements contained in the guidance include standard process validation protocols, end product sterility testing, stability trials, and robust impurity management mechanisms (including pyrogen detection). The document elaborates on the need for process controls at each manufacturing step, including batch scale and blending strategies. Storage conditions, hold times, and material controls are subjected to stringent documentation and testing to ensure product consistency and patient safety.

Importantly, any genetically modified phages or products produced via recombinant technology will be subject to EU advanced therapy medicinal product (ATMP) regulatory requirements in addition to those specified in this new phage guidance. The EMA emphasizes that while PTMP development overlaps with biologic drug regulation, the evolutionary dynamics and genetic characteristics of phages demand distinct evaluation pathways.

This draft guidance reflects broad consultation with leading microbiologists, pharmaceutical manufacturers, and regulatory scientists. Industry stakeholders are invited to provide input during the public comment period, with the final guideline expected to influence pharmaceutical R&D strategy, contract manufacturing, regulatory compliance, and microbiology standards across Europe for years to come.